Browsing by Author "Paydas, S."
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item EMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%(2018) Sriuranpong, V.; Altundag, O.; Clingan, P.; Rizvi, N.; Frontera, O. Aren; Sezer, A.; Paydas, S.; Shavdia, M.; Bondarenko, I.; Gladkov, O.; 0000-0003-0197-6622; 0000-0003-4642-3693; W-9219-2019; F-3132-2018Item Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey(2017) Ferhanoglu, B.; Bekoz, H.; Karadurmus, N.; Paydas, S.; Gulbas, Z.; Turker, A.; Toptas, T.; Tuglular, T. Firatli; Tekgunduz, E.; Kaya, A. H.; Tastemir, N.; Arat, M.; Tanrikulu, F. Pepedil; Ozkocaman, V.; Abali, H.; Turgut, M.; Kaynar, L.; Karadogan, I.; Ozbalak, M.; Ozcan, M.; Dogu, M. H.; Hacioglu, S. Kabukcu; Yildirim, R.; Barista, I.; Demirkaya, M.; Koseoglu, F. D.; Yuksel, M. Kurt; Sonmez, M.; Toprak, S. K.Item Pertuzumab, Trastuzumab and Taxane Combination for Visceral Organ Metastatic Patients: Real Life Practice Results(2018) Esin, E.; Oksuzoglu, O. B. Cakmak; Bilici, A.; Cicin, I.; Aksoy, S.; Alacacioglu, A.; Kaplan, M. A.; Cabuk, D.; Sumbul, A. T.; Paydas, S.; Sakin, A.; Er, O.; Korkmaz, T.; Yildirim, N.; Artac, M.; Harputluoglu, H.; Yumuk, P. F.; Basaran, G.; Uluc, B. Oyan; Demirci, U.; 0000-0002-5573-906X; D-4793-2014